Literature DB >> 12444906

Impact of periodic breathing on measurement of oxygen uptake and respiratory exchange ratio during cardiopulmonary exercise testing.

Darrel P Francis1, L Ceri Davies, Keith Willson, Roland Wensel, Piotr Ponikowski, Andrew J S Coats, Massimo Piepoli.   

Abstract

Metabolic exercise testing is valuable in patients with chronic heart failure (CHF), but periodic breathing may confound the measurements. We aimed to examine the effects of periodic breathing on the measurement of oxygen uptake ( V*O(2)) and respiratory exchange ratio (RER). First, we measured the effects of different averaging procedures on peak V*O(2) and RER values in 122 patients with CHF undergoing cardiopulmonary exercise testing. Secondly, we studied the effects of periodic breathing on V*O2) and RER in healthy volunteers performing computer-guided periodic breathing. Thirdly, we used a Fourier analysis to study the effects of periodic breathing on gas exchange measurements. The first part of the study showed that 1 min moving window gave a mean peak V*O(2) of 13.8 ml.min(-1).kg(-1) for the CHF patients. A 15 s window gave significantly higher values. The difference averaged 1.0 ml.min(-1).kg(-1) ( P <0.0001), but varied widely: 41% of subjects showed a difference greater than 1.0 ml.min(-1).kg(-1). RER values were also higher by an average of 0.09 ( P <0.0001); in 20% of subjects the difference was greater than 0.10. In the second part of the study, we found artefactual elevations of peak V*O(2) (without averaging) of 2.9 ml.min(-1).kg(-1) ( P <0.01) and of peak RER of 0.13 ( P <0.001), which were still significant when 30 s averaging was applied [delta(peak V*O(2))=1.8 ml.min(-1).kg(-1), P <0.01; deltaRER=0.08, P <0.001]. The third, theoretical, part of the study showed that values of carbon dioxide output and V*O(2) oscillate with different phases and amplitudes, resulting in oscillations in their ratio, RER. Averaging over 15 s or 30 s can be expected to give only 10% or 36% attenuation respectively. Thus periodic breathing causes variable artefactual elevations of measured peak V*O(2) and RER, which can be attenuated by using longer averaging periods. Clinical reports and research publications describing peak V*O(2) in CHF should be accompanied by details of the averaging technique used.

Entities:  

Mesh:

Year:  2002        PMID: 12444906     DOI: 10.1042/cs1030543

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  5 in total

1.  Increased interbreath variability of gas exchange during exercise in children with cardiomyopathy.

Authors:  Tony Reybrouck; Steven Vangesselen; Luc Mertens; Marc Gewillig
Journal:  Heart       Date:  2007-03       Impact factor: 5.994

2.  Reproducibility of onset and recovery oxygen uptake kinetics in moderately impaired patients with chronic heart failure.

Authors:  Hareld M C Kemps; Wouter R De Vries; Adwin R Hoogeveen; Maria L Zonderland; Eric J M Thijssen; Goof Schep
Journal:  Eur J Appl Physiol       Date:  2007-02-03       Impact factor: 3.078

3.  Exercise Oscillatory Ventilation: Interreviewer Agreement and a Novel Determination.

Authors:  Clinton A Brawner; Jonathan K Ehrman; Jonathan Myers; Paul Chase; Baruch Vainshelboim; Shadi Farha; Matthew A Saval; Rita McGuire; Bunny Pozehl; Steven J Keteyian
Journal:  Med Sci Sports Exerc       Date:  2018-02       Impact factor: 5.411

4.  Oxygen uptake kinetics in chronic heart failure: clinical and physiological aspects.

Authors:  H M C Kemps; G Schep; J Hoogsteen; E J M Thijssen; W R De Vries; M Zonderland; P Doevendans
Journal:  Neth Heart J       Date:  2009-06       Impact factor: 2.380

5.  Proportional Assist Ventilation Improves Leg Muscle Reoxygenation After Exercise in Heart Failure With Reduced Ejection Fraction.

Authors:  Audrey Borghi-Silva; Cassia da Luz Goulart; Cláudia R Carrascosa; Cristino Carneiro Oliveira; Danilo C Berton; Dirceu Rodrigues de Almeida; Luiz Eduardo Nery; Ross Arena; J Alberto Neder
Journal:  Front Physiol       Date:  2021-06-21       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.